Nasdaq OMX approves Cantargia for listing on First North Stockholm

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE USA, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.

Cantargia AB (“Cantargia”) has fulfilledthe requirements for listing on Nasdaq First North Stockholm, and the marketplace has now issued formal approval to the company. The first day of trading in Cantargia’s shares and warrants of series TO 3 and TO 4 is expected to be 17 March 2015.
 
Göran Forsberg, CEO, comments:
“The successful public offering that was completed in January/February is an evidence of the strong interest that exists in Cantargia, which is very encouraging. We look forward to the listing and the exciting journey in front of us.”

Upcoming investor events
In connection to the listing Cantargia’s CEO, Göran Forsberg, will be participating at a number of investor meetings, where he will present the company.

• 17 March 2015, 18.30-19.00, Investor Forum, Redeye AB, Mäster Samuelsgatan 42, Stockholm.
• 18 March 2015, 15.50-16.20, InvestorDagen, Radisson Blu Scandinavia Hotel, Amager Boulevard 70, Copenhagen.
• 26 March 2015, 14.15-14.45, Sedermeradagen, Medicon Village, Scheelevägen 2, Lund.

Certified Adviser
Sedermera Fondkommission is the company’s Certified Adviser in connection with the planned listing on Nasdaq First North Stockholm.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

Cantargia AB (reg.no. 556791-6019) is a biotech company that is developing an antibody-based cancer treatment, which attacks cancer stem cells as well as mature cancer cells. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, IL1RAP, in cancer stem cells in patients with leukaemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The company has selected a product candidate for future studies in humans. Preclinical trials with Cantargia’s antibodies have shown a potent antileukaemic effect. Parallel studies have shown an even higher expression of IL1RAP in certain solid tumours. In 2015 Cantargia will be carrying out the studies required for authorisation of clinical trials.

wkr0006.pdf